Literature DB >> 22431062

The pathological roles of BART miRNAs in nasopharyngeal carcinoma.

Angela K-F Lo1, Christopher W Dawson, Dong-Yan Jin, Kwok-Wai Lo.   

Abstract

Nasopharyngeal carcinoma (NPC) is a distinct type of head and neck cancer prevalent in south-east Asia and southern China, where it constitutes a significant health burden. Although the close association of NPC with Epstein-Barr virus (EBV) infection has been known for more than four decades, the exact role that EBV plays in the pathogenesis of this malignancy is still unclear. While NPC tumours are known to express a number of EBV-encoded proteins, they also express a large number of virus-encoded microRNAs (miRNAs), the most abundant of which are those encoded from the BamHI-A region of the viral genome: the so-called BART miRNAs. miRNAs are small non-coding mRNAs that negatively regulate the expression of various genes at the post-transcriptional level. Accumulating evidence suggests that miRNAs play important roles in tumourigenesis. Here, we review the role of EBV-encoded BART miRNAs in modulating apoptosis and host innate defence mechanisms and their contribution to NPC pathogenesis. The rationale and strategies for therapeutic targeting of BART miRNAs in EBV-infected NPC are also discussed.
Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22431062     DOI: 10.1002/path.4025

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  40 in total

Review 1.  EBV Noncoding RNAs.

Authors:  Rebecca L Skalsky; Bryan R Cullen
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

2.  Epstein-Barr virus serology as a potential screening marker for nasopharyngeal carcinoma among high-risk individuals from multiplex families in Taiwan.

Authors:  Anna E Coghill; Wan-Lun Hsu; Ruth M Pfeiffer; Hedy Juwana; Kelly J Yu; Pei-Jen Lou; Cheng-Ping Wang; Jen-Yang Chen; Chien-Jen Chen; Jaap M Middeldorp; Allan Hildesheim
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-04-27       Impact factor: 4.254

Review 3.  RNA families in Epstein-Barr virus.

Authors:  Walter N Moss; Nara Lee; Genaro Pimienta; Joan A Steitz
Journal:  RNA Biol       Date:  2013-12-20       Impact factor: 4.652

4.  Clustered microRNAs of the Epstein-Barr virus cooperatively downregulate an epithelial cell-specific metastasis suppressor.

Authors:  Teru Kanda; Mamiko Miyata; Makoto Kano; Satoru Kondo; Tomokazu Yoshizaki; Hisashi Iizasa
Journal:  J Virol       Date:  2014-12-17       Impact factor: 5.103

Review 5.  Historical review of the causes of cancer.

Authors:  Clarke Brian Blackadar
Journal:  World J Clin Oncol       Date:  2016-02-10

Review 6.  The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.

Authors:  Chi Man Tsang; Sai Wah Tsao
Journal:  Virol Sin       Date:  2015-04-21       Impact factor: 4.327

Review 7.  Epstein-barr virus and the pathogenesis of T and NK lymphoma: a mystery unsolved.

Authors:  Lindsay C George; Martin Rowe; Christopher P Fox
Journal:  Curr Hematol Malig Rep       Date:  2012-12       Impact factor: 3.952

8.  Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma.

Authors:  Xi Zeng; Juanjuan Xiang; Minghua Wu; Wei Xiong; Hailin Tang; Min Deng; Xiayu Li; Qianjin Liao; Bo Su; Zhaohui Luo; Yanhong Zhou; Ming Zhou; Zhaoyang Zeng; Xiaoling Li; Shourong Shen; Cijun Shuai; Guiyuan Li; Jiasheng Fang; Shuping Peng
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

9.  Epstein-Barr virus microRNA BART10-3p promotes dedifferentiation and proliferation of nasopharyngeal carcinoma by targeting ALK7.

Authors:  Wei-Jie Luo; Shi-Wei He; Wen-Qing Zou; Yin Zhao; Qing-Mei He; Xiao-Jing Yang; Rui Guo; Yan-Ping Mao
Journal:  Exp Biol Med (Maywood)       Date:  2021-08-23

10.  miR-26a inhibits invasion and metastasis of nasopharyngeal cancer by targeting EZH2.

Authors:  Li Yu; Juan Lu; Bao Zhang; Xiong Liu; Lu Wang; Si-Yang Li; Xiao-Hong Peng; Xia Xu; Wen-Dong Tian; Xiang-Ping Li
Journal:  Oncol Lett       Date:  2013-02-04       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.